Alissa Visram

809 total citations
57 papers, 403 citations indexed

About

Alissa Visram is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Alissa Visram has authored 57 papers receiving a total of 403 indexed citations (citations by other indexed papers that have themselves been cited), including 50 papers in Hematology, 32 papers in Molecular Biology and 25 papers in Oncology. Recurrent topics in Alissa Visram's work include Multiple Myeloma Research and Treatments (46 papers), Protein Degradation and Inhibitors (24 papers) and Peptidase Inhibition and Analysis (11 papers). Alissa Visram is often cited by papers focused on Multiple Myeloma Research and Treatments (46 papers), Protein Degradation and Inhibitors (24 papers) and Peptidase Inhibition and Analysis (11 papers). Alissa Visram collaborates with scholars based in Canada, United States and Israel. Alissa Visram's co-authors include Shaji Kumar, Taxiarchis Kourelis, Jordan J. Feld, Angela Dispenzieri, Robert A. Kyle, S. Vincent Rajkumar, Scott McComb, Seung‐Hwan Lee, Donald Bastin and Rahma Warsame and has published in prestigious journals such as SHILAP Revista de lepidopterología, Blood and PLoS ONE.

In The Last Decade

Alissa Visram

50 papers receiving 395 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Alissa Visram Canada 12 244 198 158 76 53 57 403
Ender Soydan Türkiye 8 181 0.7× 140 0.7× 121 0.8× 83 1.1× 94 1.8× 26 399
Jae-Sook Ahn South Korea 10 271 1.1× 78 0.4× 118 0.7× 68 0.9× 22 0.4× 19 388
Donald Woytowitz United States 11 90 0.4× 477 2.4× 172 1.1× 146 1.9× 36 0.7× 19 731
Honghui Huang China 14 76 0.3× 123 0.6× 183 1.2× 63 0.8× 79 1.5× 37 471
Giovanni Marconi Italy 10 199 0.8× 93 0.5× 166 1.1× 56 0.7× 20 0.4× 58 360
Katja Matthes Germany 8 117 0.5× 238 1.2× 91 0.6× 120 1.6× 29 0.5× 18 376
Giovenzio Genestreti Italy 13 90 0.4× 261 1.3× 196 1.2× 21 0.3× 85 1.6× 35 533
Anna Tasidou Greece 9 187 0.8× 106 0.5× 233 1.5× 43 0.6× 34 0.6× 13 375
Raya Mawad United States 13 264 1.1× 214 1.1× 127 0.8× 98 1.3× 18 0.3× 38 459
Christopher Strouse United States 9 159 0.7× 94 0.5× 129 0.8× 19 0.3× 23 0.4× 49 319

Countries citing papers authored by Alissa Visram

Since Specialization
Citations

This map shows the geographic impact of Alissa Visram's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alissa Visram with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alissa Visram more than expected).

Fields of papers citing papers by Alissa Visram

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alissa Visram. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alissa Visram. The network helps show where Alissa Visram may publish in the future.

Co-authorship network of co-authors of Alissa Visram

This figure shows the co-authorship network connecting the top 25 collaborators of Alissa Visram. A scholar is included among the top collaborators of Alissa Visram based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alissa Visram. Alissa Visram is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Mian, Hira, Alissa Visram, Suzanne Trudel, et al.. (2025). Minimal Residual Disease Testing Infrastructure in Multiple Myeloma: Guidance for Clinical Trial and Routine Practice Use in Canada. Clinical Lymphoma Myeloma & Leukemia. 25(6). e404–e410.
2.
Thomas, L., Risa Shorr, Alissa Visram, et al.. (2025). CAR-NK cells to treat patients with cancer: a systematic scoping review of published studies and registered clinical trials. Cytotherapy. 27(10). 1179–1189. 1 indexed citations
3.
Visram, Alissa, et al.. (2024). Treatment of elderly and frail myeloma patients. La Presse Médicale. 54(1). 104266–104266.
4.
Sandhu, Irwindeep, Michael P. Chu, Kathryn N. Rankin, et al.. (2024). Incidence and Prevalence of Clinically Detected Smoldering Multiple Myeloma Among the General Population. Blood. 144(Supplement 1). 1912–1912.
5.
Mian, Hira, Hsien Seow, Matthew C. Cheung, et al.. (2024). A Prognostic Survival Model Incorporating Patient-Reported Outcomes for Transplant-Ineligible Patients With Multiple Myeloma. The Oncologist. 29(6). 519–526. 2 indexed citations
6.
Chakraborty, Rajshekhar, Bram Rochwerg, Alissa Visram, et al.. (2024). Quadruplet regimens for patients with newly diagnosed multiple myeloma: a systematic review and meta-analysis. Blood Advances. 8(23). 5993–6002. 8 indexed citations
7.
Côté, Julie Anne, Rami Kotb, Richard LeBlanc, et al.. (2024). First Line Treatment of Newly Diagnosed Transplant Eligible Multiple Myeloma Recommendations From a Canadian Consensus Guideline Consortium. Clinical Lymphoma Myeloma & Leukemia. 25(3). e151–e172.
8.
Visram, Alissa, Kelvin Chan, Hsien Seow, et al.. (2024). Comparing the clinical trial efficacy <i>versus</i> real-world effectiveness of treatments for multiple myeloma: a population-based study. Haematologica. 110(1). 228–233.
9.
Visram, Alissa, Hsien Seow, Gregory R. Pond, et al.. (2023). Treatment Patterns and Healthcare Resource Utilization Among Patients with Triple Class Exposed Multiple Myeloma: A Population-Based Cohort Study. Blood. 142(Supplement 1). 3774–3774. 1 indexed citations
10.
Visram, Alissa, Suzanne R. Hayman, Angela Dispenzieri, et al.. (2023). A phase 1/2 of carfilzomib and melphalan conditioning for autologous stem cell transplantation for multiple myeloma (CARAMEL). American Journal of Hematology. 98(8). 1277–1285. 1 indexed citations
11.
Visram, Alissa, S. Vincent Rajkumar, Prashant Kapoor, et al.. (2022). Second- and third-line treatment strategies in multiple myeloma: a referral-center experience. Blood Cancer Journal. 12(12). 164–164. 6 indexed citations
12.
Visram, Alissa, Celine M. Vachon, Linda B. Baughn, et al.. (2021). Family history of plasma cell disorders is associated with improved survival in MGUS, multiple myeloma, and systemic AL amyloidosis. Leukemia. 36(4). 1058–1065. 4 indexed citations
13.
Saleh, Abdullah S. Al, Alissa Visram, Eli Muchtar, et al.. (2021). Treatment and outcome of newly diagnosed multiple myeloma patients > 75 years old: a retrospective analysis. Leukemia & lymphoma. 62(12). 3011–3018. 2 indexed citations
14.
Visram, Alissa, S. Vincent Rajkumar, Prashant Kapoor, et al.. (2021). Assessing the prognostic utility of smoldering multiple myeloma risk stratification scores applied serially post diagnosis. Blood Cancer Journal. 11(11). 186–186. 16 indexed citations
15.
Visram, Alissa, Camilia Soof, S. Vincent Rajkumar, et al.. (2021). Serum BCMA levels predict outcomes in MGUS and smoldering myeloma patients. Blood Cancer Journal. 11(6). 120–120. 33 indexed citations
16.
Visram, Alissa, et al.. (2021). Practical management and assessment of primary plasma cell leukemia in the novel agent era. Cancer Treatment and Research Communications. 28. 100414–100414. 3 indexed citations
17.
Vaxman, Iuliana, Alissa Visram, Shaji Kumar, et al.. (2020). Autologous stem cell transplantation for multiple myeloma patients aged ≥ 75 treated with novel agents. Bone Marrow Transplantation. 56(5). 1144–1150. 12 indexed citations
18.
Saleh, Abdullah S. Al, Iuliana Vaxman, Alissa Visram, et al.. (2020). Prognostic value of NT-ProBNP and troponin T in patients with light chain amyloidosis and kidney dysfunction undergoing autologous stem cell transplantation. Bone Marrow Transplantation. 56(1). 274–277. 2 indexed citations
19.
Saleh, Abdullah S. Al, Alissa Visram, Rahma Warsame, et al.. (2020). Prognostic Implications of Rising Serum Monoclonal Protein and Free Light Chains after Autologous Stem Cell Transplantation in Patients with Multiple Myeloma. Transplantation and Cellular Therapy. 27(4). 309.e1–309.e5. 1 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ender Soydan Breakdown of academic impact, for papers by Jae-Sook Ahn Breakdown of academic impact, for papers by Donald Woytowitz Breakdown of academic impact, for papers by Honghui Huang Breakdown of academic impact, for papers by Giovanni Marconi Breakdown of academic impact, for papers by Katja Matthes Breakdown of academic impact, for papers by Giovenzio Genestreti Breakdown of academic impact, for papers by Anna Tasidou Breakdown of academic impact, for papers by Raya Mawad Breakdown of academic impact, for papers by Christopher Strouse
Rankless by CCL
2026